mogamulizumab

Known as: Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer 
A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
0102020042018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2015
2015
This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti-CC… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
2015
2015
PURPOSE The CC chemokine receptor 4 (CCR4) is expressed on malignant T cells in cutaneous T-cell lymphoma (CTCL) as well as on… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
In this issue of Blood, Duvic et al demonstrate that mogamulizumab, a humanized monoclonal antibody targeting the chemokine… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE CC chemokine receptor 4 (CCR4) is expressed by peripheral T-cell lymphomas (PTCLs) and is associated with poor outcomes… (More)
Is this relevant?
2013
2013
We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized… (More)
Is this relevant?
2012
2012
Mogamulizumab (Poteligeo®) is a defucosylated, humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4… (More)
Is this relevant?
2012
2012
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved… (More)
Is this relevant?
2012
2012
At least 15 glyco-engineered antibodies are currently being evaluated in clinical studies. The next approval of a glycoengineered… (More)
  • figure 1
  • figure 2
Is this relevant?